ENGNW
enGene Therapeutics Inc.
Price Chart
Latest Quote
$0.28
+0.05 (+21.76%)
Current Price
| Previous Close | $0.23 |
| Open | $2.10 |
| Day High | $0.28 |
| Day Low | $0.28 |
| Volume | 22,649 |
Stock Information
| Total Debt | $33.35M |
| Cash Equivalents | $258.46M |
| Net Income | $-126.85M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-126.85M |
| Book/sh | $3.81 |
| Employees | 81 |
Financial Ratios
| Quick Ratio | 12.17 |
| Current Ratio | 12.57 |
| Debt/Eq | 13.07 |
Returns & Margins
| ROA | -28.86% |
| ROE | -52.59% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.07 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.23 |
| SMA50 | $2.23 |
| RSI | nan |
| Shares Float | 22.49M |
| Volatility | -0.29 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| YTD | -33.03% |
| 10 Years | -33.03% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.23 | 0 |
| 2026-06-17 | $2.23 | 0 |
| 2026-06-16 | $2.23 | 0 |
| 2026-06-15 | $2.23 | 0 |
| 2026-06-12 | $2.23 | 0 |
| 2026-06-11 | $2.23 | 0 |
| 2026-06-10 | $2.23 | 0 |
| 2026-06-09 | $2.23 | 0 |
| 2026-06-08 | $2.23 | 0 |
| 2026-06-05 | $2.23 | 0 |
| 2026-06-04 | $2.23 | 0 |
| 2026-06-03 | $2.23 | 0 |
| 2026-06-02 | $2.23 | 0 |
| 2026-06-01 | $2.23 | 0 |
| 2026-05-29 | $2.23 | 0 |
| 2026-05-28 | $2.23 | 0 |
| 2026-05-27 | $2.23 | 0 |
| 2026-05-26 | $2.23 | 0 |
| 2026-05-22 | $2.23 | 0 |
| 2026-05-21 | $2.23 | 0 |
| 2026-05-20 | $2.23 | 0 |
| 2026-05-19 | $2.23 | 0 |
About enGene Therapeutics Inc.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
đ° Latest News
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
MarketBeat âĸ 2026-03-15T21:33:00Z
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference
MarketBeat âĸ 2026-03-15T20:37:48Z
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
MarketBeat âĸ 2026-03-15T19:03:00Z
enGene Holdings (ENGN) Is Up 36.9% After Strong Phase 2 Bladder Cancer Gene Therapy Results
Simply Wall St. âĸ 2025-11-13T08:17:08Z
enGeneâs NMIBC gene therapy touts 63% complete response in pivotal trial
Clinical Trials Arena âĸ 2025-11-11T17:04:42Z
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
MT Newswires âĸ 2025-11-11T14:15:04ZThis enGene Holdings Insider Increased Their Holding In The Last Year
Simply Wall St. âĸ 2025-08-19T12:20:59Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $2,994,000 | $2,798,000 | $4,953,000 | $1,423,000 |
| Total Expenses | $123,165,000 | $62,297,000 | $26,060,000 | $19,427,000 |
| Other Income Expense | $-569,000 | $-479,000 | $-70,004,000 | $-3,719,000 |
| Other Non Operating Income Expenses | $-569,000 | $-113,000 | $-56,341,000 | $-662,000 |
| Net Non Operating Interest Income Expense | $6,432,000 | $7,615,000 | $-3,836,000 | $-1,294,000 |
| Interest Expense Non Operating | $2,994,000 | $2,798,000 | $4,953,000 | $1,423,000 |
| Operating Expense | $123,165,000 | $62,297,000 | $26,060,000 | $19,427,000 |
| General And Administrative Expense | $28,685,000 | $23,982,000 | $8,470,000 | $3,260,000 |
| Other Operating Expenses | - | $1,879,000 | $1,132,000 | $700,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-117,302,000 | $-55,142,000 | $-99,917,000 | $-24,462,000 |
| Net Interest Income | $6,432,000 | $7,615,000 | $-3,836,000 | $-1,294,000 |
| Interest Income | $9,426,000 | $10,413,000 | $1,117,000 | $129,000 |
| Normalized Income | $-117,302,000 | $-54,776,110 | $-91,719,200 | $-22,206,240 |
| Net Income From Continuing And Discontinued Operation | $-117,302,000 | $-55,142,000 | $-99,917,000 | $-24,462,000 |
| Total Operating Income As Reported | $-123,165,000 | $-62,297,000 | $-26,060,000 | $-19,427,000 |
| Net Income Common Stockholders | $-117,302,000 | $-55,142,000 | $-104,739,000 | $-29,024,000 |
| Net Income | $-117,302,000 | $-55,142,000 | $-99,917,000 | $-24,462,000 |
| Net Income Including Noncontrolling Interests | $-117,302,000 | $-55,142,000 | $-99,917,000 | $-24,462,000 |
| Net Income Continuous Operations | $-117,302,000 | $-55,142,000 | $-99,917,000 | $-24,462,000 |
| Pretax Income | $-117,302,000 | $-55,161,000 | $-99,900,000 | $-24,440,000 |
| Special Income Charges | $0 | $-366,000 | $-3,091,000 | $0 |
| Interest Income Non Operating | $9,426,000 | $10,413,000 | $1,117,000 | $129,000 |
| Operating Income | $-123,165,000 | $-62,297,000 | $-26,060,000 | $-19,427,000 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-110 | $-5,465,200 | $-801,240 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-113,799,000 | $-51,674,000 | $-81,109,000 | $-19,722,000 |
| Total Unusual Items | $0 | $-366,000 | $-13,663,000 | $-3,057,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-366,000 | $-13,663,000 | $-3,057,000 |
| Reconciled Depreciation | $509,000 | $323,000 | $175,000 | $238,000 |
| EBITDA (Bullshit earnings) | $-113,799,000 | $-52,040,000 | $-94,772,000 | $-22,779,000 |
| EBIT | $-114,308,000 | $-52,363,000 | $-94,947,000 | $-23,017,000 |
| Diluted NI Availto Com Stockholders | $-117,302,000 | $-55,142,000 | $-104,739,000 | $-29,024,000 |
| Tax Provision | $0 | $-19,000 | $17,000 | $22,000 |
| Research And Development | $94,480,000 | $38,315,000 | $16,458,000 | $15,467,000 |
| Selling General And Administration | $28,685,000 | $23,982,000 | $8,470,000 | $3,260,000 |
| Other Gand A | $11,471,000 | $11,951,000 | $3,690,000 | $1,205,000 |
| Salaries And Wages | $17,214,000 | $12,031,000 | $4,780,000 | $2,055,000 |
| Other Special Charges | - | $366,000 | $3,091,000 | - |
| Preferred Stock Dividends | - | - | $4,822,000 | $4,562,000 |
| Gain On Sale Of Security | - | - | $-10,572,000 | $-3,057,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $167,710,000 | $272,612,000 | $72,486,000 | $-23,496,000 |
| Total Assets | $221,468,000 | $311,173,000 | $86,959,000 | $23,909,000 |
| Total Non Current Assets | $20,077,000 | $63,811,000 | $1,519,000 | $1,326,000 |
| Other Non Current Assets | $1,362,000 | $1,374,000 | $930,000 | $939,000 |
| Investmentin Financial Assets | $8,522,000 | $59,527,000 | $0 | - |
| Current Assets | $201,391,000 | $247,362,000 | $85,440,000 | $22,583,000 |
| Other Current Assets | $6,649,000 | $8,626,000 | $1,500,000 | $739,000 |
| Restricted Cash | $79,000 | $72,000 | $76,000 | $74,000 |
| Receivables | $927,000 | $332,000 | $2,343,000 | $1,336,000 |
| Taxes Receivable | $927,000 | $332,000 | $2,343,000 | $1,336,000 |
| Cash Cash Equivalents And Short Term Investments | $193,736,000 | $238,332,000 | $81,521,000 | $20,434,000 |
| Cash And Cash Equivalents | $50,152,000 | $173,004,000 | $81,521,000 | $20,434,000 |
| Debt | ||||
| Total Debt | $31,795,000 | $25,022,000 | $9,778,000 | $32,110,000 |
| Long Term Debt And Capital Lease Obligation | $21,779,000 | $23,900,000 | $9,216,000 | $30,845,000 |
| Long Term Debt | $15,324,000 | $22,473,000 | $9,216,000 | $30,845,000 |
| Current Debt And Capital Lease Obligation | $10,016,000 | $1,122,000 | $562,000 | $1,265,000 |
| Current Debt | $8,002,000 | $699,000 | $562,000 | $1,265,000 |
| Other Current Borrowings | $8,002,000 | $699,000 | $562,000 | $1,265,000 |
| Net Debt | - | - | - | $11,676,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $53,758,000 | $38,561,000 | $14,473,000 | $47,405,000 |
| Total Non Current Liabilities Net Minority Interest | $21,779,000 | $23,900,000 | $9,216,000 | $42,301,000 |
| Current Liabilities | $31,979,000 | $14,661,000 | $5,257,000 | $5,104,000 |
| Other Current Liabilities | $577,000 | $225,000 | $113,000 | - |
| Payables And Accrued Expenses | $17,333,000 | $9,839,000 | $3,768,000 | $3,163,000 |
| Payables | $6,707,000 | $1,411,000 | $1,195,000 | $745,000 |
| Total Tax Payable | $19,000 | $0 | $39,000 | $22,000 |
| Income Tax Payable | $19,000 | $0 | $39,000 | $22,000 |
| Accounts Payable | $6,688,000 | $1,411,000 | $1,156,000 | $723,000 |
| Derivative Product Liabilities | - | - | $0 | $11,456,000 |
| Equity | ||||
| Common Stock Equity | $167,710,000 | $272,612,000 | $72,486,000 | $-76,614,000 |
| Total Equity Gross Minority Interest | $167,710,000 | $272,612,000 | $72,486,000 | $-23,496,000 |
| Stockholders Equity | $167,710,000 | $272,612,000 | $72,486,000 | $-23,496,000 |
| Gains Losses Not Affecting Retained Earnings | $-888,000 | $-1,419,000 | $-1,016,000 | $-1,016,000 |
| Other Equity Adjustments | $-888,000 | $-1,419,000 | $-1,016,000 | $-1,016,000 |
| Retained Earnings | $-372,032,000 | $-254,730,000 | $-199,588,000 | $-99,671,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $53,118,000 |
| Preferred Stock Equity | - | - | - | $53,118,000 |
| Other | ||||
| Ordinary Shares Number | $52,018,658 | $50,976,676 | $23,197,976 | $23,197,976 |
| Share Issued | $52,018,658 | $50,976,676 | $23,197,976 | $23,197,976 |
| Tangible Book Value | $167,710,000 | $272,612,000 | $72,486,000 | $-76,614,000 |
| Invested Capital | $191,036,000 | $295,784,000 | $82,264,000 | $-44,504,000 |
| Working Capital | $169,412,000 | $232,701,000 | $80,183,000 | $17,479,000 |
| Capital Lease Obligations | $8,469,000 | $1,850,000 | $0 | $0 |
| Total Capitalization | $183,034,000 | $295,085,000 | $81,702,000 | $7,349,000 |
| Additional Paid In Capital | $27,349,000 | $18,950,000 | $13,717,000 | $7,683,000 |
| Capital Stock | $513,281,000 | $509,811,000 | $259,373,000 | $69,508,000 |
| Common Stock | $513,281,000 | $509,811,000 | $259,373,000 | $16,390,000 |
| Long Term Capital Lease Obligation | $6,455,000 | $1,427,000 | $0 | - |
| Current Capital Lease Obligation | $2,014,000 | $423,000 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,053,000 | $3,475,000 | $814,000 | $676,000 |
| Current Accrued Expenses | $10,626,000 | $8,428,000 | $2,573,000 | $2,418,000 |
| Investments And Advances | $8,522,000 | $59,527,000 | $0 | - |
| Available For Sale Securities | $8,522,000 | $59,527,000 | - | - |
| Net PPE | $10,193,000 | $2,910,000 | $589,000 | $387,000 |
| Accumulated Depreciation | $-2,103,000 | $-1,610,000 | $-1,727,000 | $-1,553,000 |
| Gross PPE | $12,296,000 | $4,520,000 | $2,316,000 | $1,940,000 |
| Leases | $262,000 | $239,000 | $129,000 | $122,000 |
| Other Properties | $3,134,000 | $2,191,000 | $1,779,000 | $1,472,000 |
| Machinery Furniture Equipment | $1,184,000 | $349,000 | $408,000 | $346,000 |
| Buildings And Improvements | $7,716,000 | $1,741,000 | $0 | $0 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $143,584,000 | $65,328,000 | $0 | - |
| Preferred Stock | - | - | $0 | $53,118,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-100,724,000 | $-49,206,000 | $-25,061,000 | $-17,745,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-99,239,000 | $-48,281,000 | $-24,743,000 | $-17,592,000 |
| Cash Flow From Continuing Operating Activities | $-99,239,000 | $-48,281,000 | $-24,743,000 | $-17,592,000 |
| Operating Gains Losses | $3,000 | $382,000 | $14,152,000 | $3,703,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,485,000 | $-925,000 | $-318,000 | $-153,000 |
| Investing Cash Flow | $-25,138,000 | $-125,953,000 | $-318,000 | $-153,000 |
| Cash Flow From Continuing Investing Activities | $-25,138,000 | $-125,953,000 | $-318,000 | $-153,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $260,149,000 | $56,892,000 | $0 |
| Financing Cash Flow | $1,524,000 | $265,716,000 | $86,147,000 | $27,967,000 |
| Cash Flow From Continuing Financing Activities | $1,524,000 | $265,716,000 | $86,147,000 | $27,967,000 |
| Net Common Stock Issuance | $0 | $260,149,000 | $56,892,000 | $0 |
| Common Stock Issuance | $0 | $260,149,000 | $56,892,000 | $0 |
| Net Other Financing Charges | - | $-13,584,000 | $-4,058,000 | $-435,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-699,000 | $-9,445,000 | $-4,731,000 | $-1,010,000 |
| Issuance Of Debt | $0 | $22,500,000 | $38,000,000 | $29,400,000 |
| Interest Paid Supplemental Data | $2,289,000 | $1,925,000 | $1,398,000 | $615,000 |
| End Cash Position | $50,152,000 | $173,004,000 | $81,521,000 | $20,434,000 |
| Beginning Cash Position | $173,004,000 | $81,521,000 | $20,434,000 | $11,017,000 |
| Effect Of Exchange Rate Changes | $1,000 | $1,000 | $1,000 | $-805,000 |
| Changes In Cash | $-122,853,000 | $91,482,000 | $61,086,000 | $10,222,000 |
| Proceeds From Stock Option Exercised | $2,223,000 | $6,096,000 | $44,000 | $12,000 |
| Net Issuance Payments Of Debt | $-699,000 | $13,055,000 | $33,269,000 | $28,390,000 |
| Net Long Term Debt Issuance | $-699,000 | $13,055,000 | $33,269,000 | $28,390,000 |
| Long Term Debt Payments | $-699,000 | $-9,445,000 | $-4,731,000 | $-1,010,000 |
| Long Term Debt Issuance | $0 | $22,500,000 | $38,000,000 | $29,400,000 |
| Net Investment Purchase And Sale | $-23,653,000 | $-125,028,000 | $0 | - |
| Sale Of Investment | $137,190,000 | $0 | - | - |
| Purchase Of Investment | $-160,843,000 | $-125,028,000 | $0 | - |
| Net PPE Purchase And Sale | $-1,485,000 | $-925,000 | $-318,000 | $-153,000 |
| Purchase Of PPE | $-1,485,000 | $-925,000 | $-318,000 | $-153,000 |
| Change In Working Capital | $9,740,000 | $95,000 | $-517,000 | $2,174,000 |
| Change In Other Current Liabilities | $274,000 | $-49,000 | $0 | - |
| Change In Payables And Accrued Expense | $8,072,000 | $5,699,000 | $1,241,000 | $2,144,000 |
| Change In Accrued Expense | $3,130,000 | $5,225,000 | $868,000 | $2,341,000 |
| Change In Payable | $4,942,000 | $474,000 | $373,000 | $-197,000 |
| Change In Account Payable | $4,942,000 | $474,000 | $373,000 | $-197,000 |
| Change In Prepaid Assets | $1,989,000 | $-7,566,000 | $-751,000 | $-113,000 |
| Change In Receivables | $-595,000 | $2,011,000 | $-1,007,000 | $143,000 |
| Other Non Cash Items | $1,232,000 | $969,000 | $1,702,000 | $639,000 |
| Stock Based Compensation | $9,646,000 | $5,324,000 | $3,450,000 | $116,000 |
| Amortization Of Securities | $-3,067,000 | $-232,000 | $0 | - |
| Depreciation Amortization Depletion | $509,000 | $323,000 | $175,000 | $238,000 |
| Depreciation And Amortization | $509,000 | $323,000 | $175,000 | $238,000 |
| Depreciation | $509,000 | $323,000 | $175,000 | $238,000 |
| Net Foreign Currency Exchange Gain Loss | $3,000 | $-6,000 | $489,000 | $646,000 |
| Gain Loss On Sale Of PPE | $0 | $22,000 | $0 | - |
| Net Income From Continuing Operations | $-117,302,000 | $-55,142,000 | $-99,917,000 | $-24,462,000 |
| Unrealized Gain Loss On Investment Securities | - | $0 | $56,212,000 | $0 |
| Gain Loss On Investment Securities | - | - | $10,572,000 | $3,057,000 |
| Sale Of PPE | - | - | - | $0 |
Fetched: 2026-06-17